Literature DB >> 8968890

Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

R K Straubinger1, B A Summers, Y F Chang, M J Appel.   

Abstract

In specific-pathogen-free dogs experimentally infected with Borrelia burgdorferi by tick exposure, treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection. Although joint disease was prevented or cured in five of five amoxicillin- and five of six doxycycline-treated dogs, skin punch biopsies and multiple tissues from necropsy samples remained PCR positive and B. burgdorferi was isolated from one amoxicillin- and two doxycycline-treated dogs following antibiotic treatment. In contrast, B. burgdorferi was isolated from six of six untreated infected control dogs and joint lesions were found in four of these six dogs. Serum antibody levels to B. burgdorferi in all dogs declined after antibiotic treatment. Negative antibody levels were reached in four of six doxycycline- and four of six amoxicillin-treated dogs. However, in dogs that were kept in isolation for 6 months after antibiotic treatment was discontinued, antibody levels began to rise again, presumably in response to proliferation of the surviving pool of spirochetes. Antibody levels in untreated infected control dogs remained high.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8968890      PMCID: PMC229521          DOI: 10.1128/jcm.35.1.111-116.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  43 in total

1.  Animal models for Lyme disease.

Authors:  S W Barthold
Journal:  Lab Invest       Date:  1995-02       Impact factor: 5.662

Review 2.  Persisting symptoms of Lyme disease--possible explanations and implications for treatment.

Authors:  L H Sigal
Journal:  J Rheumatol       Date:  1994-04       Impact factor: 4.666

3.  Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment.

Authors:  S E Malawista; S W Barthold; D H Persing
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

4.  Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement.

Authors:  V Sambri; S Armati; R Cevenini
Journal:  FEMS Immunol Med Microbiol       Date:  1993-06

5.  The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study.

Authors:  N A Shadick; C B Phillips; E L Logigian; A C Steere; R F Kaplan; V P Berardi; P H Duray; M G Larson; E A Wright; K S Ginsburg; J N Katz; M H Liang
Journal:  Ann Intern Med       Date:  1994-10-15       Impact factor: 25.391

6.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis.

Authors:  A D Alexander; P L Rule
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients.

Authors:  D H Persing; B J Rutledge; P N Rys; D S Podzorski; P D Mitchell; K D Reed; B Liu; E Fikrig; S E Malawista
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

9.  Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans.

Authors:  J Nowakowski; R B Nadelman; G Forseter; D McKenna; G P Wormser
Journal:  J Am Acad Dermatol       Date:  1995-02       Impact factor: 11.527

10.  A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein.

Authors:  A Sadziene; M Jonsson; S Bergström; R K Bright; R C Kennedy; A G Barbour
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more
  82 in total

1.  PCR-Based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-Day postinfection period.

Authors:  R K Straubinger
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Remains of infection.

Authors:  Alan Barbour
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

3.  Duration of immunity to reinfection with tick-transmitted Borrelia burgdorferi in naturally infected mice.

Authors:  J Piesman; M C Dolan; C M Happ; B J Luft; S E Rooney; T N Mather; W T Golde
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 4.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  The Lyme law.

Authors:  Elizabeth Zubek
Journal:  CMAJ       Date:  2015-04-21       Impact factor: 8.262

Review 6.  Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?

Authors:  Emir Hodzic
Journal:  Bosn J Basic Med Sci       Date:  2015-07-08       Impact factor: 3.363

7.  Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it?

Authors:  Linda K Bockenstedt; Justin D Radolf
Journal:  Clin Infect Dis       Date:  2014-02-11       Impact factor: 9.079

8.  A new animal model for studying Lyme disease spirochetes in a mammalian host-adapted state.

Authors:  D R Akins; K W Bourell; M J Caimano; M V Norgard; J D Radolf
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

Review 9.  Chronic Lyme disease: a review.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

10.  Follow-up of Bernese Mountain dogs and other dogs with serologically diagnosed Borrelia burgdorferi infection: what happens to seropositive animals?

Authors:  Bernhard Gerber; Katharina Haug; Simone Eichenberger; Claudia E Reusch; Max M Wittenbrink
Journal:  BMC Vet Res       Date:  2009-05-08       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.